Item 1. Financial Statements
Item 1. Financial Statements.
JACKSON ACQUISITION COMPANY II
CONDENSED BALANCE SHEET
SEPTEMBER 30, 2024
Assets
Current assets
Prepaid expenses
$ 3,249
Total current assets
3,249
Deferred offering costs
190,551
Total Assets
$ 193,800
Liabilities and Shareholders’ Deficit
Current Liabilities
Accrued offering costs
$ 93,000
Accounts payable and accrued expenses
5,000
Promissory note - related party
120,368
Total Liabilities
218,368
Commitments and Contingencies (Note 6)
Shareholders’ Deficit
Preference shares, $ 0.0001 par value; 1,000,000 shares authorized; none issued or outstanding
—
Class A ordinary shares, $ 0.0001 par value; 200,000,000 shares authorized; none issued or outstanding
—
Class B ordinary shares, $ 0.0001 par value; 20,000,000 shares authorized; 5,750,000 shares issued and outstanding (1)
575
Additional paid-in capital
24,425
Accumulated deficit
( 49,568 )
Total Shareholders’ Deficit
( 24,568 )
Total Liabilities and Shareholders’ Deficit
$ 193,800
(1) Includes
an aggregate of up to 750,000 Class B ordinary shares subject to forfeiture by the holders thereof depending on the extent to which
the underwriter’s over-allotment option is exercised (see Note 5). On December 11, 2024, the Company consummated its IPO and
sold 23,000,000 Units, including 3,000,000 Units sold pursuant to the full exercise of the underwriters’ option to purchase additional
units to cover the over-allotment, hence the 750,000 shares of Class B ordinary shares were no longer subject to forfeiture.
The accompanying notes are an integral part of
the unaudited condensed financial statements.
1
JACKSON ACQUISITION COMPANY II
CONDENSED STATEMENT OF OPERATIONS
FOR THE PERIOD FROM SEPTEMBER 11, 2024 (INCEPTION)
THROUGH SEPTEMBER 30, 2024
(UNAUDITED)
General and administrative costs
$ 49,568
Loss from operations
( 49,568 )
Net loss
$ ( 49,568 )
Weighted average shares outstanding, Class B ordinary shares (1)
5,000,000
Basic and diluted net loss per share, Class B ordinary shares
$ ( 0.01 )
(1) Excludes
an aggregate of up to 750,000 Class B ordinary shares subject to forfeiture by the holders thereof depending on the extent to which
the underwriter’s over-allotment option is exercised (see Note 5). On December 11, 2024, the Company consummated its IPO and
sold 23,000,000 Units, including 3,000,000 Units sold pursuant to the full exercise of the underwriters’ option to purchase additional
units to cover the over-allotment, hence the 750,000 shares of Class B ordinary shares were no longer subject to forfeiture.
The accompanying notes are an integral part of
the unaudited condensed financial statements.
2
JACKSON ACQUISITION COMPANY II
CONDENSED STATEMENT OF CHANGES IN SHAREHOLDERS’
DEFICIT
(UNAUDITED)
FOR THE PERIOD FROM SEPTEMBER 11, 2024 (INCEPTION)
THROUGH SEPTEMBER 30, 2024
Class A
Ordinary Shares
Class B
Ordinary Shares
Additional
Paid-in
Accumulated
Total
Shareholders’
Shares
Amount
Shares
Amount
Capital
Deficit
Deficit
Balance — September 11, 2024 (Inception)
—
$
—
—
$
—
$
—
$
—
$
—
Issuance of Class B ordinary shares to Sponsor (1)
—
—
5,750,000
575
24,425
—
25,000
Net loss
—
—
—
—
—
( 49,568
)
( 49,568
)
Balance – September 30, 2024 (Unaudited)
—
$
—
5,750,000
$
575
$
24,425
$
( 49,568
)
$
( 24,568
)
(1) Includes an aggregate of up to 750,000 Class B ordinary shares subject to forfeiture by the holders thereof depending on the extent to which the underwriter’s over-allotment option is exercised (see Note 5). On December 11, 2024, the Company consummated its IPO and sold 23,000,000 Units, including 3,000,000 Units sold pursuant to the full exercise of the underwriters’ option to purchase additional units to cover the over-allotment, hence the 750,000 shares of Class B ordinary shares were no longer subject to forfeiture.
The accompanying notes are an integral part of
the unaudited condensed financial statements.
3
JACKSON ACQUISITION COMPANY II
CONDENSED STATEMENT OF CASH FLOWS
FOR THE PERIOD FROM SEPTEMBER 11, 2024 (INCEPTION)
THROUGH SEPTEMBER 30, 2024
(UNAUDITED)
Cash Flows from Operating Activities:
Net loss
$ ( 49,568 )
Adjustments to reconcile net loss to net cash used in operating activities:
Formation costs (included in general and administrative costs) paid
via issuance of founder shares
8,148
Payment of general and administrative costs via promissory
note
36,420
Changes in operating assets and liabilities:
Accrued expenses
5,000
Net cash used in operating activities
—
Net Change in Cash
—
Cash – Beginning of period
—
Cash – End of period
$ —
Non-Cash investing and financing activities:
Deferred offering costs included in accrued offering costs
$ 93,000
Deferred offering costs paid through promissory note - related party
$ 83,948
Deferred offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares
$ 2,753
Deferred offering costs contributed by sponsor through promissory note
$ 10,850
Prepaid services contributed in exchange for issuance of Class B ordinary shares
$ 22,247
The accompanying notes are an integral part of
the unaudited condensed financial statements.
4
JACKSON ACQUISITION COMPANY II
NOTES TO CONDENSED
FINANCIAL STATEMENTS
SEPTEMBER 30, 2024 (UNAUDITED)
NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS
Jackson Acquisition Company II (the “Company”)
is a blank check company incorporated as a Cayman Islands exempted company on September 11, 2024. The Company was incorporated for
the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with
one or more businesses (“Business Combination”).
While the Company may pursue an initial business
combination target in any industry or geographic location, the Company intends to focus its search for a target business by concentrating
its efforts in identifying high-quality businesses with a focus on healthcare services, healthcare technology, or otherwise focused on
the healthcare industry. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the
risks associated with early stage and emerging growth companies.
As of September 30, 2024, the Company had not
commenced any operations. All activity for the period from September 11, 2024 (inception) through September 30, 2024, relates to
the Company’s formation and the initial public offering (“Initial Public Offering”), which is described below. The Company
will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate
non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected
December 31 as its fiscal year end.
The registration statement for the Company’s
Initial Public Offering was declared effective on December 9, 2024. On December 11, 2024, the Company consummated the Initial Public Offering
of 23,000,000 units (the “Units” and, with respect to the shares of Class A ordinary shares included in the Units being offered,
the “Public Shares”), which includes the full exercise by the underwriters of their over-allotment option in the amount of
3,000,000 Units, at $ 10.00 per Unit, generating gross proceeds of $ 230,000,000 , which is described in Note 3. Simultaneously with the
closing of the Initial Public Offering, the Company consummated the sale of 840,000 private placement units (each, a “Private Placement
Unit”) at a price of $ 10.00 per Private Placement Unit in a private placement to RJ Healthcare SPAC II, LLC (the “Sponsor”)
and Roth Capital Partners, LLC, representative of the underwriters (“Roth”), generating gross proceeds of $ 8,400,000 , which
is described in Notes 4.
Transaction costs amounted to $ 5,157,741 , consisting
of $ 4,600,000 of cash underwriting fee and $ 557,741 of other offering costs.
The Company’s management has broad discretion
with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Units,
although substantially all of the net proceeds are intended to be applied generally toward completing a Business Combination. The Company
must complete its initial Business Combination with one or more target businesses that together have a fair market value equal to at least
80 % of the assets held in the Trust Account (as defined below) (net of amounts disbursed to management for working capital purposes and
excluding the amount of any deferred underwriting discount held in trust) at the time of the agreement to enter into a Business Combination.
The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50 % or more of the issued
and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it
not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment
Company Act”). There is no assurance that the Company will be able to successfully effect a Business Combination.
Following the closing of the Initial Public Offering
on December 11, 2024, an amount of $ 232,300,000 ($ 10.10 per Unit) from the net proceeds of the sale of the Units, and a portion of the
net proceeds from the sale of the Private Placement Units, was placed in the trust account (“Trust Account”), located in the
United States, with Continental Stock Transfer & Trust Company acting as trustee. The funds will be held in cash, including in demand
deposit accounts at a bank, or invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market
funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury
obligations; the holding of these assets in this form is intended to be temporary and for the sole purpose of facilitating the intended
Business Combination. To mitigate the risk that the Company might be deemed to be an investment company for purposes of the Investment
Company Act, which risk increases the longer the Company holds investments in the Trust Account, the Company may, at any time instruct
the trustee to liquidate the investments held in the Trust Account and instead to hold the funds in the Trust Account in cash or in an
interest bearing demand deposit account at a bank. Except with respect to interest earned on the funds held in the Trust Account that
may be released to the Company to pay its taxes, the proceeds from the Initial Public Offering and the sale of the Private Placement Units
will not be released from the Trust Account until the earliest of (i) the completion of the Company’s initial Business Combination,
(ii) the redemption of the Company’s public shares if the Company is unable to complete the initial Business Combination within
24 months from the closing of the Initial Public Offering or by such earlier liquidation date as the Company’s board of directors
may approve (the “Completion Window”), subject to applicable law, or (iii) the redemption of the Company’s public shares
properly submitted in connection with a shareholder vote to amend the Company’s amended and restated memorandum and articles of
association to (A) modify the substance or timing of the Company’s obligation to allow redemption in connection with the initial
Business Combination or to redeem 100 % of the Company’s public shares if the Company has not consummated an initial Business Combination
within the Completion Window or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial
Business Combination activity. The proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors,
if any, which could have priority over the claims of the Company’s public shareholders.
5
The Company will provide the Company’s public
shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either
(i) in connection with a general meeting called to approve the Business Combination or (ii) by means of a tender offer. The
decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by
the Company. The public shareholders will be entitled to redeem their shares for a pro rata portion of the amount held in the Trust
Account (initially $ 10.10 per share), calculated as of two business days prior to the completion of a Business Combination, including
any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations.
There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s rights. The Class A
ordinary shares were recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering,
in accordance with Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity.”
If the Company seeks shareholder approval in connection
with a Business Combination, it will complete a Business Combination only if it obtains the approval of an ordinary resolution under Cayman
Islands law, which requires the affirmative vote of a majority of the shareholders who vote at a general meeting of the Company. If a
shareholder vote is not required under applicable law or stock exchange listing requirements and the Company does not decide to hold a
shareholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association,
conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (“SEC”), and file tender
offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing
a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor, officer and
directors have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased in or after the Initial Public
Offering in favor of approving a Business Combination (except that any Public Shares such parties may purchase in compliance with the
requirements of Rule 14e-5 under the Exchange Act would not be voted in favor of approving the business combination transaction) and to
waive its redemption rights with respect to any such shares in connection with a shareholder vote to approve a Business Combination. Additionally,
each public shareholder may elect to redeem its Public Shares, without voting, and if they do vote, irrespective of whether they vote
for or against a proposed Business Combination.
Notwithstanding the foregoing, if the Company
seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Company’s
Amended and Restated Memorandum and Articles of Association provides that a public shareholder, together with any affiliate of such shareholder
or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its
shares with respect to more than an aggregate of 15 % of the Public Shares without the Company’s prior written consent.
The Sponsor has agreed (a) to waive its redemption
rights with respect to any Founder Shares and Public Shares held by it in connection with the completion of a Business Combination and
(b) not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (i) to modify the substance
or timing of the Company’s obligation to redeem 100 % of the Public Shares if the Company does not complete a Business Combination
within the Combination Period (as defined below) or (ii) with respect to any other provision relating to shareholders’ rights
or pre-initial business combination activity, unless the Company provides the public shareholders with the opportunity to redeem their
Public Shares in conjunction with any such amendment and (iii) to waive its rights to liquidating distributions from the Trust Account
with respect to the Founder Shares if the Company fails to complete a Business Combination.
6
The Company will have until 24 months from
the closing of the Initial Public Offering (the “Combination Period”) to complete a Business Combination. If the Company is
unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the
purpose of winding up, (ii) as promptly as reasonably possible but no more than 10 business days thereafter, redeem 100 % of
the outstanding Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account,
including interest earned (less up to $ 100,000 of interest to pay dissolution expenses and net of taxes payable), divided by the number
of then outstanding Public Shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including
the right to receive further liquidation distributions, if any), and (iii) as promptly as reasonably possible following such redemption,
subject to the approval of the remaining shareholders and the Company’s board of directors, liquidate and dissolve, subject in each
case to its obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.
The Sponsor has agreed to waive its liquidation
rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However,
if the Sponsor acquires Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions
from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriter has agreed
to waive its rights to its Business Combination Marketing Fee (see Note 6) held in the Trust Account in the event the Company does
not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held
in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible
that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit
($ 10.00 ).
The Sponsor has agreed that it will be liable
to the Company, if and to the extent any claims by a third party for services rendered or products sold to the Company, or by a prospective
target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account
to below (1) $ 10.10 per Public Share or (2) such lesser amount per Public Share held in the Trust Account as of the date of
the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the amount of interest which
may be withdrawn to pay taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any
and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriter
of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended
(the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party,
the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility
that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers
(other than the Company’s independent auditors), prospective target businesses or other entities with which the Company does business,
execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.
Liquidity and Capital Resources
As of September 30, 2024, the Company had no cash
and a working capital deficit of $ 215,119 . Further, the Company has incurred and expects to continue to incur significant costs in pursuit
of its acquisition plans. There is no assurance that the Company’s plans to raise capital will be successful. In connection with
the Company’s assessment of going concern considerations in accordance with Accounting Standards Codification 205-40, “Going
Concern,” as of September 30, 2024, and including the closing of the Initial Public Offering on December 11, 2024, the Company has
sufficient funds for the working capital needs of the Company until a minimum of one year from the date of issuance of these financial
statements. The Company cannot assure that its plans to raise capital or to consummate an initial Business Combination will be successful.
7
Risks and Uncertainties
The United States and global markets are
experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and the
recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization
(“NATO”) deployed additional military forces to eastern Europe, and the United States, the United Kingdom, the European
Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and
entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication
payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other
assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of Ukraine by Russia and
the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken in the future, by NATO,
the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global
security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts
are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital
markets, as well as supply chain interruptions and increased cyberattacks against U.S. companies. Additionally, any resulting sanctions
could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.
Any of the above-mentioned factors, or any other
negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine,
the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely affect the Company’s search
for an initial business combination and any target business with which the Company may ultimately consummate an initial Business Combination.
NOTE 2. SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying unaudited condensed financial
statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”)
for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain
information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or
omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information
and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management,
the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are
necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
8
The accompanying unaudited condensed financial
statements should be read in conjunction with the Company’s prospectus for its Initial Public Offering as filed with the SEC on
December 11, 2024, as well as the Company’s Current Report on Form 8-K, as filed with the SEC on December 17, 2024. The interim
results for the period from September 11, 2024 (inception) through September 30, 2024, are not necessarily indicative of the results to
be expected for the period ending December 31, 2024 or for any future periods.
Emerging Growth Company
The Company is an “emerging growth company,”
as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the
“JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other
public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation
requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS
Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies
(that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that
a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies
but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means
that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison
of the Company’s financial statement with another public company which is neither an emerging growth company nor an emerging growth
company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting
standards used.
Use of Estimates
The preparation of the financial statements in
conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements.
Making estimates requires management to exercise
significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances
that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near
term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents
The Company considers all short-term investments
with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash and no cash equivalents
as of September 30, 2024.
9
Deferred Offering Costs
The Company complies with the requirements of
the ASC 340-10-S99 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A — “Expenses of Offering.”
Deferred offering costs consist principally of professional and registration fees that are related to the Initial Public Offering. FASB
ASC 470-20, “Debt with Conversion and Other Options,” addresses the allocation of proceeds from the issuance of convertible
debt into its equity and debt components. The Company applies this guidance to allocate Initial Public Offering proceeds from the Units between
Class A ordinary shares and rights, using the residual method by allocating Initial Public Offering proceeds first to assigned value
of the rights and then to the Class A ordinary shares. On the date of the Initial Public Offering, on December 11, 2024, offering
costs allocated to the Class A ordinary shares were charged to temporary equity and offering costs allocated to the Public Share
Rights and Private Placement Rights were charged to shareholders’ equity as Public Share Rights and Private Placement Rights after
management’s evaluation were accounted for under equity treatment.
Income Taxes
The Company accounts for income taxes under ASC 740,
“Income Taxes” (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities
for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected
future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance
to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.
ASC 740 also clarifies the accounting for
uncertainty in income taxes recognized in an enterprise’s financial statement and prescribes a recognition threshold and measurement
process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those
benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company
recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits
and no amounts accrued for interest and penalties as of September 30, 2024. The Company is currently not aware of any issues under review
that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax
examinations by major taxing authorities since inception.
The Company is considered an exempted Cayman Islands
company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States.
As such, the Company’s tax provision was zero for the period presented.
Concentration of Credit Risk
Financial instruments that potentially subject
the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal
Deposit Insurance Corporation coverage limit of $ 250,000 . Any loss incurred or a lack of access to such funds could have a significant
adverse impact on the Company’s financial condition, results of operations, and cash flows.
Fair Value of Financial Instruments
The fair value of the Company’s assets and
liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying
amounts represented in the accompanying balance sheet, primarily due to their short-term nature.
Share Rights
The Company accounts for the Public Share Rights
and Private Placement Rights issued in connection with the Initial Public Offering and the private placement in accordance with the guidance
contained in FASB ASC Topic 815, “Derivatives and Hedging”. Accordingly, the Company evaluated and classified the rights under
equity treatment at its assigned value.
Net Loss per Ordinary Share
Net loss per ordinary share is computed by dividing
net loss by the weighted average number of ordinary shares outstanding during the period, excluding ordinary shares subject to forfeiture.
Weighted average shares were reduced for the effect of an aggregate of 750,000 ordinary shares that were subject to forfeiture by the
holders thereof depending on the extent to which the underwriter’s over-allotment option was exercised (see Note 5). At September
30, 2024, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into
ordinary shares and then share in the earnings of the Company. As a result, diluted loss per ordinary share is the same as basic loss
per ordinary share for the periods presented.
10
Recently Issued Accounting Standards
Management does not believe that any other recently
issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s condensed
financial statement.
NOTE 3. INITIAL PUBLIC OFFERING
Pursuant to the Initial Public Offering, on December
11, 2024, the Company sold 23,000,000 Units, which includes the full exercise by the underwriters of their over-allotment option in the
amount of 3,000,000 Units, at a price of $ 10.00 per Unit. Each Unit consists of one Class A ordinary share and one right entitling the
holder thereof to receive one tenth (1/10) of one Class A ordinary share upon the consummation of an initial Business Combination, as
described in more detail below (the “Public Share Rights”). Each ten Public Share Rights entitle the holder thereof to receive
one Class A ordinary share at the closing of an initial Business Combination. The Company will not issue fractional Class A ordinary shares.
NOTE 4. PRIVATE PLACEMENT
Simultaneously with the closing of the Initial
Public Offering, the Sponsor and Roth purchased an aggregate of 840,000 Private Placement Units ( 495,000 Private Placement Units purchased
by the Sponsor and 345,000 Private Placement Units purchased by Roth or its designees), at a price of $ 10.00 per Private Placement Unit
from the Company in a private placement, generating gross proceeds of $ 8,400,000 . A portion of the proceeds from the sale of the Private
Placement Units was added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete
a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units held in the Trust Account
will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law). The Private Placement Units
(including the underlying ordinary shares (“Private Placement Shares”) and rights (“Private Placement Rights”))
are identical to the Public Units (including the underlying Public Shares and Public Share Rights) sold in the Initial Public Offering.
NOTE 5. RELATED PARTY TRANSACTIONS
Founder Shares
On September 13, 2024, the Sponsor paid $ 25,000
to cover certain offering and formation costs of the Company in consideration for 5,750,000 Class B ordinary shares (the “Founder
Shares”) issued to the Sponsor. Up to 750,000 of the Founder Shares were to be surrendered by the Sponsor for no consideration depending
on the extent to which the underwriters’ over-allotment was exercised. On December 11, 2024, the underwriters exercised their over-allotment
option in full as part of the closing of the Initial Public Offering. As such, the 750,000 founder shares are no longer subject to forfeiture.
On November 18, 2024, the Sponsor transferred 200,000 Founder Shares
to the Company’s officers and directors at their original purchase price. The sale of the Founder Shares to the Company’s
directors and director’s nominees is in the scope of FASB ASC Topic 718, “Compensation-Stock Compensation” (“ASC
718”). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant
date. The fair value of the 200,000 shares granted to the Company’s director nominees was $ 206,000 or $ 1.03 per share. The Founder
Shares were granted subject to a performance condition (i.e., the occurrence of a Business Combination). Compensation expense related
to the Founders Shares is recognized only when the performance condition is probable of occurrence under the applicable accounting literature.
As of September 30, 2024, the Company determined that a Business Combination is not considered probable, and, therefore, no stock-based
compensation expense has been recognized. Stock-based compensation would be recognized at the date a Business Combination is considered
probable (i.e., upon consummation of a Business Combination) in an amount equal to the number of Founder Shares times the grant date fair
value per share (unless subsequently modified) less the amount initially received for the purchase of the Founder Shares.
11
The Company’s initial shareholders have
agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of (A) one
year after the completion of a Business Combination; and (B) subsequent to a Business Combination, (x) if the last reported
sale price of the Class A ordinary shares equals or exceeds $ 12.00 per share (as adjusted for share subdivisions, share capitalizations,
reorganizations, recapitalizations and the like) for any 20 trading days within any 30 -trading day period commencing at least
150 days after a Business Combination, or (y) the date on which the Company completes a liquidation, merger, amalgamation, share
exchange, reorganization or other similar transaction that results in all of the Company’s shareholders having the right to exchange
their Class A ordinary shares for cash, securities or other property.
Promissory Note — Related Parties
On September 13, 2024, the Company issued
an unsecured promissory note to RJ Healthcare SPAC II, LLC (the “Promissory Note”), pursuant to which the Company may
borrow up to an aggregate principal amount of $ 300,000 . The Promissory Note is non-interest bearing and payable on the earlier of (i) March 31,
2025 or (ii) the consummation of the Initial Public Offering. As of September 30, 2024, there was $ 120,368 outstanding under the
Promissory Note.
Administrative Services Agreement
The Company entered into an agreement with the
Sponsor, commencing on December 9, 2024 through the earlier of the Company’s consummation of a Business Combination and its liquidation,
to pay an aggregate of $ 10,000 per month for office space and administrative and support services.
Related Party Loans
In order to finance transaction costs in connection
with a Business Combination, either of the Sponsor, any of their respective affiliates or certain of the Company’s directors and
officers may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company
completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released
to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that
a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital
Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms
of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working
Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion,
up to $ 1,500,000 of such Working Capital Loans for each such person may be convertible into Units of the post-Business Combination
entity at a price of $ 10.00 per Unit. The Units would be identical to the Private Placement Units. As of September 30, 2024, there
are no Working Capital Loans outstanding.
NOTE 6. COMMITMENTS AND CONTINGENCIES
Registration Rights
The holders of the Founder Shares, Private Placement
Shares, Private Placement Units, and any units that may be issued upon conversion of the Working Capital Loans (and any Class A ordinary
shares issuable upon the exercise of the Private Placement Units and units that may be issued upon conversion of Working Capital Loans
and upon conversion of the Founder Shares) will be entitled to registration rights pursuant to a registration rights agreement to be signed
on the effective date of Initial Public Offering requiring the Company to register such securities for resale (in the case of the Founder
Shares, only after conversion to Class A ordinary shares). The holders of these securities will be entitled to make up to three demands,
excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggyback”
registration rights with respect to registration statements filed subsequent to completion of a Business Combination and rights to require
the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights
agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become
effective until termination of the applicable lock-up period. The registration rights agreement does not contain liquidating damages or
other cash settlement provisions resulting from delays in registering the Company’s securities. The Company will bear the expenses
incurred in connection with the filing of any such registration statements.
12
Underwriting Agreement
The underwriters had a 45-day option from the
date of the Initial Public Offering to purchase up to an additional 3,000,000 units to cover over-allotments, if any. On December 11,
2024, simultaneously with the closing of the Initial Public Offering, the underwriters elected to fully exercise the over-allotment option
to purchase the additional 3,000,000 Units at a price of $ 10.00 per Unit.
The underwriters were paid a cash underwriting
discount of $ 4,000,000 ( 2.0 % of the gross proceeds of the units offered in the Initial Public Offering, excluding any proceeds from units
sold pursuant to the underwriters’ over-allotment option) on December 11, 2024, the date of the Initial Public Offering.
Business Combination Marketing Fee
The Company engaged Roth, on December 9, 2024,
as an advisor in connection with its Business Combination. The Company will pay Roth a cash fee (the “Business Combination Marketing
Fee”) for such services upon the consummation of its initial Business Combination in an amount up to 4.0 % of the gross proceeds
of the Initial Public Offering, an aggregate of up to $ 9,200,000 after the underwriters exercised their over-allotment option in full
on December 11, 2024. As of September 30, 2024, no Business Combination Marketing Fee has been incurred or recorded.
NOTE 7. SHAREHOLDERS’ DEFICIT
Preference Shares — The
Company is authorized to issue 1,000,000 preference shares with a par value of $ 0.0001 per share, with such designations, voting and other
rights and preferences as may be determined from time to time by the Company’s board of directors. At September 30, 2024, there
were no preference shares issued or outstanding.
Class A Ordinary Shares — The
Company is authorized to issue 200,000,000 Class A ordinary shares, with a par value of $ 0.0001 per share. Holders of Class A
ordinary shares are entitled to one vote for each share. At September 30, 2024, there were no shares of Class A ordinary shares issued
or outstanding.
Class B Ordinary Shares — The
Company is authorized to issue 20,000,000 Class B ordinary shares, with a par value of $ 0.0001 per share. Holders of the Class B
ordinary shares are entitled to one vote for each share. On September 13, 2024, the Company issued 5,750,000 Class B ordinary shares to
the Sponsor for $ 25,000 , or approximately $ 0.004 per share. As of September 30, 2024, there were 5,750,000 Class B ordinary shares issued
and outstanding.
Only holders of Class B ordinary shares will
have the right to vote on the election of directors prior to the Business Combination. Holders of Class A ordinary shares and holders
of Class B ordinary shares will vote together as a single class on all other matters submitted to a vote of the Company’s shareholders
except as otherwise required by law.
The Class B ordinary shares will automatically
convert into Class A ordinary shares at the time of a Business Combination or earlier at the option of the holder, on a one-for-one
basis, subject to adjustment. In the case that additional Class A ordinary shares, or equity-linked securities, are issued or deemed
issued in excess of the amounts issued in the Initial Public Offering and related to the closing of a Business Combination, the ratio
at which the Class B ordinary shares will convert into Class A ordinary shares will be adjusted (unless the holders of a majority
of the issued and outstanding Class B ordinary shares agree to waive such anti-dilution adjustment with respect to any such issuance
or deemed issuance) so that the number of Class A ordinary shares issuable upon conversion of all Class B ordinary shares will
equal, in the aggregate, on an as-converted basis, 20 % of the sum of all ordinary shares issued and outstanding upon the completion of
the Initial Public Offering plus all Class A ordinary shares and equity-linked securities issued or deemed issued in connection with
a Business Combination, excluding any shares or equity-linked securities issued, or to be issued, to any seller in a Business Combination.
13
Rights
Except in cases where the Company is not the surviving
company in a business combination, each holder of a right will automatically receive one-tenth (1/10) of one Class A ordinary share upon
consummation of the initial Business Combination, even if the holder of a public right redeemed all Class A ordinary shares held by it
in connection with the initial Business Combination or an amendment to the amended and restated memorandum and articles of association
with respect to the pre-business combination activities. In the event the Company will not be the surviving company upon completion of
the initial Business Combination, each holder of a right will be required to affirmatively convert its rights in order to receive the
one-tenth (1/10) of one Class A ordinary share underlying each right upon consummation of the Business Combination. No additional consideration
will be required to be paid by a holder of rights in order to receive its additional Class A ordinary shares upon consummation of an initial
Business Combination. The shares issuable upon exchange of the rights will be freely tradable (except to the extent held by affiliates
of the Company). If the Company enters into a definitive agreement for a Business Combination in which it will not be the surviving entity,
the definitive agreement will provide for the holders of rights to receive the same per share consideration the holders of the Class A
ordinary shares will receive in the transaction on an as-converted into Class A ordinary share basis.
The Company will not issue fractional shares in
connection with an exchange of rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed
in accordance with the applicable provisions of Cayman Islands Law. As a result, holders must hold rights in multiples of ten in order
to receive shares for all of their rights upon closing of a Business Combination. If the Company is unable to complete an initial Business
Combination within the required time period and the Company liquidates the funds held in the Trust Account, holders of rights will not
receive any of such funds with respect to their rights, nor will they receive any distribution from the assets held outside of the Trust
Account with respect to such rights, and the rights will expire worthless. Further, there are no contractual penalties for failure to
deliver securities to the holders of the rights upon consummation of an initial Business Combination. Additionally, in no event will the
Company be required to net cash settle the rights. Accordingly, the rights may expire worthless.
NOTE 8. SUBSEQUENT EVENTS
The Company evaluated subsequent events and transactions
that occurred after the balance sheet date up to the date that the condensed financial statements were issued. Based upon this review,
other than as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in
the condensed financial statements.
On November 18, 2024, the Sponsor transferred
an aggregate of 200,000 Founder Shares to the Company’s officers and directors at their original purchase price. The fair value
of the 200,000 shares granted to the Company’s officers and directors was $ 206,000 or $ 1.03 per share. The Founder Shares were granted
subject to a performance condition (i.e., the occurrence of a Business Combination).
On December 11, 2024, the Company consummated
the Initial Public Offering of 23,000,000 Units, which includes the full exercise by the underwriters of their over-allotment option in
the amount of 3,000,000 Units, at $ 10.00 per Unit, generating gross proceeds of $ 230,000,000 , which is described in Note 3. Simultaneously
with the closing of the Initial Public Offering, the Company consummated the sale of 840,000 Private Placement Units at a price of $ 10.00
per Private Placement Unit in a private placement to the Sponsor and Roth, generating gross proceeds of $ 8,400,000 , which is described
in Note 4.
On December 11, 2024, in connection with the closing of the Initial
Public Offering, the underwriters were paid $ 4,000,000 .
14
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.